Plain-English translation of NCT07145918 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can safely and effectively treat schizophrenia. The study has two parts: one will test different doses of the medication over 2–3 weeks, and the other will test it over 6 weeks in people experiencing a recent flare-up of symptoms. About 268 people will participate across roughly 32 sites in the United States.
Schizophrenia is a serious mental illness that affects how people think, perceive reality, and understand themselves. Researchers want to see if this new treatment might offer a safe and effective option for managing these symptoms.
You likely qualify if…
You likely don't qualify if…
You'll take either the new medication or a placebo (a pill with no active ingredient) by mouth, depending on which group you're assigned to. Part A participants will take their assigned pill for 2–3 weeks, while Part B participants will take theirs for 6 weeks. You'll attend regular clinic visits for blood tests, symptom assessments, side effect checks, and questionnaires, then be followed for 30 days after you stop taking the medication to ensure your safety.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States